HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the year ended December 31, 2011.
Full Year Highlights
"In 2011 we registered a moderate top line growth in a very challenging year for the pharmaceutical industry in China. Once again our diversified product portfolio demonstrated its robustness in a difficult environment," said Ms. Zhilin Li, China Pharma's Chairman and CEO. "The healthcare reform has produced encouraging results in improving the standards of living for people in China. The changes produced by the reform, however, have created pricing pressures on nearly all pharmaceutical products across the industry, and we expect this environment to continue for some time to come. Going forward, we expect the launches of new products such as Candesartan, our new hypertension drug, and Rosuvastatin, our generic version of Crestor, to enhance our profitability and growth opportunities. Commercializing exciting new drugs like our antibiotic combination drug, along with first-to-market generic medicines, is an important part of China Pharma's growth and profitability strategy."
Full Year Results
Revenues for the year ended December 31, 2011 were $81.2 million, up 9% from revenues of $74.4 million for the year ended December 31, 2010, reflecting higher sales in three out of four product categories.
The "Digestive Diseases" product group remains the Company's fastest growing revenue category in 2011, with sales increasing 33% to $12.4 million from $9.3 million in 2010. The strong performance of the Digestive Diseases product group primarily reflects incremental revenue from Tiopronin, and Compound Ammonium Glycyrrhetate, both prescribed for the treatment of Hepatitis and liver dysfunction diseases. Sales of "Anti-Viro/Infection & Respiratory" products, the Company's largest revenue category during 2011, grew 18% to $32.0 million from $27.1 million in 2010. The "CNS Cerebral and Cadio Vascular" product group ("CNS") generated sales of $25.8 million in 2011, representing an increase of 8% compared to sales of $23.9 million in 2010. We expect the upcoming new CNS products (namely Candesartan and Rosuvastatin) will further support the profitability and sales in this category once launched. Sales from the "Other" product category was $11.0 million in 2011 compared to $14.1 million in 2010, a decrease of 22%, as all products in this category encountered stronger competition this year compared to the last year.
Gross profit for the year ended December 31, 2011 was $29.0 million, compared to gross profit of $30.3 million in 2010, a decrease of 4%. Gross margin was 36% in 2011, compared to 41% for 2010, a decrease of five percentage points, reflecting pricing pressure during the year.
Selling, general and administrative expenses in 2011 were $7.2 million, or 8.8% of sales, compared to $5.6 million, or 7.5% of sales, in 2010. For the year ended December 31, 2011, the Company's bad debt expense was $0.1 million, compared to a bad debt expense of $0.5 million in 2010.
Operating income was $22.0 million in 2011 compared to $24.7 million in 2010, a decrease of 11%. The lower operating income in 2011 reflects lower gross margin and higher operating expenses.
For the year ended December 31, 2011, the Company paid income tax at a rate of approximately 15%. Income tax expense for the year ended December 31, 2011 was $3.4 million. While for the year ended December 31, 2010, our income tax was at a rate of approximately 11%, and our income tax expense was $2.7 million for the year ended December 31, 2010. The Company obtained "National High-Tech Enterprise" status from the PRC government in the fourth quarter of 2010. With this designation, the Company is entitled to a preferential tax rate of 15% from 2011 until 2013, which is notably lower than the statutory income tax rate of 25%.
Net income for the year 2011 was $19.3 million, or $0.44 per basic and diluted share, compared to $23.4 million, or $0.54 per basic and diluted share in 2010.
Financial Condition
As of December 31, 2011, the Company had cash and cash equivalents of $4.1 million compared to $3.7 million as of December 31, 2010. Year-over-year, working capital increased to $97 million in 2011 from $79 million in 2010 and the current ratio rose to 8.0 times from 7.1 times.
Accounts receivable balance rose to $69.7 million in 2011 from $61.9 million at the end of 2010. The Company's management team continues to be focused on improving accounts receivable collection and expects to make further progress in the quarters to come.
For the year ended December 31, 2011, cash flow from operating activities was $5.2 million, as compared to $7.8 million in 2010. Most of this decline were due to lower net income and higher working capital usage from higher inventory levels and lower accounts payables in 2011 compared to 2010.
"In 2012, we anticipate adding new higher-margin revenue streams from our upcoming new products, which should help buffer some of the margin pressures coming from competitive pricing due to government healthcare reform policies. Overall we are optimistic that we have the right mix of products and new product pipeline to position China Pharma to benefit from China's unprecedented healthcare reform program," said Ms. Li. "We believe our success in 2012 and beyond will be defined by our differentiated products, promising pipeline, strong distribution network, and commercialization expertise."
Pipeline Update
As of December 31, 2011, China Pharma had various pipeline drugs in different stages of active development. Some of these are highlighted below:
Conference Call
The Company will hold a conference call at 8:30 am ET on March 15, 2012 to discuss fiscal year 2011 results. Listeners may access the call by dialing 1-866-519-4004 or 65-672-393-81 for international callers, Conference ID # 59409919. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com. A replay of the call will be accessible through March 22, 2012 by dialing 1-866-214-5335 or 61-282-355-000 for international callers, Conference ID # 59409919.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.
Contact:
China Pharma Holdings, Inc.
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
- FINANCIAL TABLES FOLLOW -
CHINA PHARMA HOLDINGS, INC. | ||||
CONSOLIDATED BALANCE SHEETS | ||||
| ||||
|
| December 31, |
| December 31, |
|
| 2011 |
| 2010 |
ASSETS |
|
|
|
|
Current Assets: |
|
|
|
|
Cash and cash equivalents |
| $ 4,050,854 |
| $ 3,692,086 |
Banker's acceptances |
| 83,512 |
| - |
Trade accounts receivable, less allowance for doubtful |
|
|
|
|
accounts of $3,536,405 and $3,317,017, respectively |
| 69,695,556 |
| 61,947,737 |
Other receivables, less allowance for doubtful |
|
|
|
|
accounts of $38,921 and $15,669, respectively |
| 55,039 |
| 65,019 |
Advances to suppliers |
| 5,778,841 |
| 5,311,896 |
Inventory |
| 30,378,658 |
| 20,388,935 |
Deferred tax assets |
| 566,226 |
| 528,684 |
Total Current Assets |
| 110,608,686 |
| 91,934,357 |
Advances for purchases of property and equipment |
| 170,323 |
| 114,946 |
Advances for purchases of intangible assets |
| 36,194,494 |
| 29,781,388 |
Property and equipment, net of accumulated depreciation of |
|
|
|
|
$3,391,124 and $3,436,182, respectively |
| 6,334,817 |
| 6,372,487 |
Intangible assets, net of accumulated amortization of |
|
|
|
|
$3,041,804 and $2,342,081, respectively |
| 3,082,671 |
| 3,547,763 |
TOTAL ASSETS |
| $ 156,390,991 |
| $ 131,750,941 |
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current Liabilities: |
|
|
|
|
Trade accounts payable |
| $ 3,112,385 |
| $ 4,937,781 |
Accrued expenses |
| 184,017 |
| 98,206 |
Accrued taxes payable |
| 3,082,353 |
| 2,386,019 |
Other payables |
| 784,697 |
| 92,077 |
Advances from customers |
| 1,784,474 |
| 1,208,988 |
Other payables - related parties |
| 899,314 |
| 303,644 |
Short-term notes payable |
| 3,931,745 |
| 3,781,119 |
Total Current Liabilities |
| 13,778,985 |
| 12,807,834 |
Long-term deferred tax liability |
| 128,909 |
| 71,673 |
Derivative warrant liability |
| - |
| 934,260 |
Total Liabilities |
| 13,907,894 |
| 13,813,767 |
Stockholders' Equity: |
|
|
|
|
Preferred stock, $0.001 par value; 5,000,000 shares authorized; |
|
|
|
|
no shares issued or outstanding |
| - |
| - |
Common stock, $0.001 par value; 95,000,000 shares authorized; |
|
|
|
|
43,529,557 shares and 43,404,557 shares outstanding, respectively |
| 43,530 |
| 43,405 |
Additional paid-in capital |
| 23,448,534 |
| 23,252,476 |
Retained earnings |
| 104,286,666 |
| 85,017,024 |
Accumulated other comprehensive income |
| 14,704,367 |
| 9,624,269 |
Total Stockholders' Equity |
| 142,483,097 |
| 117,937,174 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
| $ 156,390,991 |
| $ 131,750,941 |
|
|
|
|
|
|
| - |
| - |
CHINA PHARMA HOLDINGS, INC. | |||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
AND COMPREHENSIVE INCOME | |||||
| |||||
|
| For the Years Ended |
| ||
|
| December 31, |
| ||
|
| 2011 |
| 2010 |
|
Revenue |
| $ 81,166,739 |
| $ 74,388,180 |
|
Cost of revenue |
| 52,178,680 |
| 44,105,447 |
|
|
|
|
|
|
|
Gross profit |
| 28,988,059 |
| 30,282,733 |
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
Selling expenses |
| 3,439,522 |
| 2,542,826 |
|
General and administrative expenses |
| 3,716,397 |
| 3,039,450 |
|
Bad debt expense |
| 108,085 |
| 505,224 |
|
Total operating expenses |
| 7,264,004 |
| 6,087,500 |
|
|
|
|
|
|
|
Government subsidy income |
| 301,672 |
| 469,509 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
| 22,025,727 |
| 24,664,742 |
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
Interest income |
| 7,208 |
| 15,413 |
|
Interest expense |
| (255,198) |
| (168,258) |
|
Derivative gain |
| 934,260 |
| 1,588,888 |
|
Net other income |
| 686,270 |
| 1,436,043 |
|
|
|
|
|
|
|
Income before income taxes |
| 22,711,997 |
| 26,100,785 |
|
Income tax expense |
| (3,442,355) |
| (2,686,438) |
|
Net income |
| 19,269,642 |
| 23,414,347 |
|
|
|
|
|
|
|
Other comprehensive income - foreign currency |
|
|
|
|
|
translation adjustment |
| 5,080,098 |
| 3,721,462 |
|
Comprehensive income |
| $ 24,349,740 |
| $ 27,135,809 |
|
|
|
|
|
|
|
Earnings per Share: |
|
|
|
|
|
Basic |
| $ 0.44 |
| $ 0.54 |
|
Diluted |
| $ 0.44 |
| $ 0.54 |
|
|
|
|
|
|
|
CHINA PHARMA HOLDINGS, INC. | ||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
| ||||
|
| For the Years Ended | ||
|
| December 31, | ||
|
| 2011 |
| 2010 |
Cash Flows from Operating Activities: |
|
|
|
|
Net income |
| $ 19,269,642 |
| $ 23,414,347 |
Depreciation and amortization |
| 1,174,822 |
| 1,505,195 |
Stock based compensation |
| 196,183 |
| 345,416 |
Derivative gain |
| (934,260) |
| (1,588,888) |
Bad debt expense |
| 108,085 |
| 505,224 |
Deferred income taxes |
| 37,281 |
| (123,177) |
Changes in assets and liabilities: |
|
|
|
|
Trade accounts and other receivables |
| (11,392,154) |
| (9,231,358) |
Advances to suppliers |
| (251,171) |
| (3,367,119) |
Inventory |
| (2,925,143) |
| (5,530,989) |
Trade accounts payable |
| (1,928,259) |
| 895,001 |
Accrued expenses and other liabilities |
| 758,783 |
| 74,063 |
Accrued taxes payable |
| 591,470 |
| 785,383 |
Other payables |
| 13,327 |
| (30,183) |
Advances from customers |
| 518,718 |
| 132,572 |
Net Cash Provided by Operating Activities |
| 5,237,324 |
| 7,785,487 |
|
|
|
|
|
Cash Flows from Investing Activities: |
|
|
|
|
Net investment in banker's acceptances |
| (82,149) |
| - |
Advances for purchases of property and equipment |
|
|
|
|
and intangible assets |
| (5,191,385) |
| (10,454,529) |
Purchase of property and equipment |
| (352,362) |
| (63,852) |
Net Cash Used in Investing Activities |
| (5,625,896) |
| (10,518,381) |
|
|
|
|
|
Cash Flows from Financing Activity: |
|
|
|
|
Proceeds from issuance of notes payable |
| - |
| 3,687,996 |
Payments of notes payable |
| - |
| (3,835,515) |
Borrowings from related party |
| 595,670 |
| 227,903 |
Proceeds from exercise of warrants |
| - |
| 2,583,000 |
Net Cash Provided by Financing Activity |
| 595,670 |
| 2,663,384 |
|
|
|
|
|
Effect of Exchange Rate Changes on Cash |
| 151,670 |
| 126,843 |
Net Increase in Cash |
| 358,768 |
| 57,333 |
Cash and Cash Equivalents at Beginning of Year |
| 3,692,086 |
| 3,634,753 |
Cash and Cash Equivalents at End of Year |
| $ 4,050,854 |
| $ 3,692,086 |
|
|
|
|
|
Supplemental Cash Flow Information: |
|
|
|
|
Cash paid for interest |
| $ 248,018 |
| $ 168,258 |
Cash paid for income taxes |
| 4,532,592 |
| 2,839,548 |
Supplemental Noncash Investing and Financing Activities: |
|
|
|
|
Accounts payable for purchases of property and equipment |
| $ 143,151 |
| $ 100,160 |
Accounts receivable collected with banker's acceptances |
| 6,102,570 |
| - |
Inventory purchased with banker's acceptances |
| 6,102,570 |
| - |
|
|
|
|
|
